Skip to content
Pharma Observatory a Scientist.com platform

Organization (Industry)

Power Life Sciences, Inc. (United States)

ClinicalTrials.gov lists Power Life Sciences, Inc. (United States) as lead sponsor of 111 trials.

US Industry
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

92 0 2022 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 1 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 6 in 2026 and about 19 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

This page covers Power Life Sciences, Inc. (United States): 111 lead-sponsored trials and 1 legal-entity registration.

Get the Power Life Sciences, Inc. (United States) report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (109)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Sarcoma 6
Lung Neoplasms 4
Anxiety Disorders 3
Colorectal Neoplasms 3
Dementia 3

Trials by start year as sponsor or collaborator (5)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 1
2025 16
2024 92
2023 1
2022 1

Recruitment duration, a model prediction: none of the 111 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Journals published in (252)

Shown in this order: most published in first.

Journals published in
Journal Publications
JAMA 10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 8
BMC cancer 5
Lancet (London, England) 5
Neurology 4

US granted patents (1)

Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.

US granted patents
US patents granted Granted in the last 5 years Most recent grant
11 0 2021-01-05

Financing and grant events (2)

Shown in this order: most recent first.

Financing and grant events
Date Round type Amount (USD) Source
2023-12-07 Private placement 11,934,978 Form d
2022-08-08 Private placement 6,909,993 Form d

Latest dated events (124)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-06 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-04 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-04 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-03 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-03 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

CLIA clinical laboratory certificates (1)

CLIA clinical laboratory certificates
Lab Certificate Status
POWER Certificate of waiver Active

Biomarker capability evidence (4)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ALK Trial sponsor Named in trial inclusion criteria
EGFR Trial sponsor Named in trial inclusion criteria
ALK Trial sponsor Mentioned in trial text
EGFR Trial sponsor Mentioned in trial text

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, sponsor delivery record, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, and biomarkers this organization publishes on.